QRD Pharma
Private Company
Funding information not available
Overview
QRD Pharma is a privately held, revenue-generating contract research organization (CRO) founded in 2022 and based in Warrington, Pennsylvania. The company provides specialized analytical services—including bioanalysis, chiral separation, and DMPK—to pharmaceutical and biotech clients, leveraging techniques like LC-MS and SFC. It has demonstrated rapid growth, expanding its lab footprint and building a diverse client base that ranges from startups to top-tier pharmaceutical companies, with a strong emphasis on data quality and fast turnaround times.
Technology Platform
GLP-compliant LC-MS bioanalysis, chiral analysis using Supercritical Fluid Chromatography (SFC), derivatization, and chiral columns, with expanding in vitro DMPK capabilities.
Opportunities
Risk Factors
Competitive Landscape
QRD Pharma competes in the fragmented bioanalytical CRO market against large, full-service global CROs (e.g., LabCorp, IQVIA) and many smaller, specialized labs. Its differentiation is based on agility, deep expertise in chiral separations using SFC, and a focus on quality and fast turnaround times for a client base ranging from startups to large pharma.